Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02708355 · ClinicalTrials.gov registry record · Phase 4
Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT02708355 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 55 participants.
The verdict
NCT02708355, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to investigate the association between gastric acid suppression and relief of 24 hour heartburn following treatment with the proton pump inhibitor (PPI) drug esomeprazole in frequent heartburn patients.
Interventions
- DRUG Placebo
- DRUG Esomeprazole 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02708355
The ClinicalTrials.gov registry entry for NCT02708355 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02708355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02708355 about?
NCT02708355 is a clinical study titled "Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment". The purpose of this pilot study is to investigate the association between gastric acid suppression and relief of 24 hour heartburn following treatment with the proton pump inhibitor (PPI) drug esomeprazole in frequent heartburn patients.
What is the current status of trial NCT02708355?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2016-01. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02708355?
The interventions under investigation include: Placebo (DRUG), Esomeprazole 20 mg (DRUG).
Who is sponsoring clinical trial NCT02708355?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.